RESUMEN
Janus Kinase 3 (JAK3) is important for the signaling transduction of cytokines in immune cells and is identified as potential target for treatment of rheumatoid arthritis (RA). Recently, we designed and synthesized two JAK3 inhibitors J1b and J1f, which featured with high selectivity but mild bioactivity. Therefore, in present study the structure was optimized to increase the potency. As shown in the results, most of the compounds synthesized showed stronger inhibitory activities against JAK3 in contrast to the lead compounds, among which 9a was the most promising candidate because it had the most potent effect in ameliorating carrageenan-induced inflammation of mice and exhibited low acute in vivo toxicity (MTD > 2 g/kg). Further analysis revealed that 9a was highly selective to JAK3 (IC50 = 0.29 nM) with only minimal effect on other JAK members (>3300-fold) and those kinases bearing a thiol in a position analogous to that of Cys909 in JAK3 (>150-fold). Meanwhile, the selectivity of JAK3 was also confirmed by PBMC stimulation assay, in which 9a irreversibly bound to JAK3 and robustly inhibited the signaling transduction with mild suppression on other JAKs. Moreover, it was showed that 9a could remarkably inhibited the proliferation of lymphocytes in response to concanavalin A and significantly mitigate disease severity in collagen induced arthritis. Therefore, present data indicate that compound 9a is a selective JAK3 inhibitor and could be a promising candidate for clinical treatment of RA.
Asunto(s)
Artritis Reumatoide , Janus Quinasa 3 , Inhibidores de Proteínas Quinasas , Pirimidinas , Janus Quinasa 3/antagonistas & inhibidores , Janus Quinasa 3/metabolismo , Artritis Reumatoide/tratamiento farmacológico , Animales , Pirimidinas/química , Pirimidinas/farmacología , Pirimidinas/síntesis química , Humanos , Relación Estructura-Actividad , Ratones , Inhibidores de Proteínas Quinasas/farmacología , Inhibidores de Proteínas Quinasas/química , Inhibidores de Proteínas Quinasas/síntesis química , Estructura Molecular , Relación Dosis-Respuesta a Droga , Pirroles/química , Pirroles/farmacología , Pirroles/síntesis química , Carragenina , Masculino , Artritis Experimental/tratamiento farmacológico , Artritis Experimental/inducido químicamente , Antirreumáticos/farmacología , Antirreumáticos/química , Antirreumáticos/síntesis química , Simulación del Acoplamiento MolecularRESUMEN
Rheumatoid arthritis (RA) is a chronic autoimmune disease. Targeting NLRP3 inflammasome, specifically its interaction with NEK7 via the LRR domain of NLRP3, is a promising therapeutic strategy. Our research aimed to disrupt this interaction by focusing on the LRR domain. Through virtual screening, we identified five compounds with potent anti-inflammatory effects and ideal LRR binding affinity. Lead compound C878-1943 underwent structural optimization, yielding pyridoimidazole derivatives with different anti-inflammatory activities. Compound I-19 from the initial series effectively inhibited caspase-1 and IL-1ß release in an adjuvant-induced arthritis (AIA) rat model, significantly reducing joint swelling and spleen/thymus indices. To further enhance potency and extend in vivo half-life, a second series including II-8 was developed, demonstrating superior efficacy and longer half-life. Both I-19 and II-8 bind to the LRR domain, inhibiting NLRP3 inflammasome activation. These findings introduce novel small molecule inhibitors targeting the LRR domain of NLRP3 protein and disrupt NLRP3-NEK7 interaction, offering a novel approach for RA treatment.
Asunto(s)
Artritis Experimental , Artritis Reumatoide , Quinasas Relacionadas con NIMA , Proteína con Dominio Pirina 3 de la Familia NLR , Proteína con Dominio Pirina 3 de la Familia NLR/antagonistas & inhibidores , Proteína con Dominio Pirina 3 de la Familia NLR/metabolismo , Quinasas Relacionadas con NIMA/antagonistas & inhibidores , Quinasas Relacionadas con NIMA/metabolismo , Animales , Artritis Reumatoide/tratamiento farmacológico , Artritis Reumatoide/metabolismo , Humanos , Ratas , Artritis Experimental/tratamiento farmacológico , Descubrimiento de Drogas , Relación Estructura-Actividad , Masculino , Inflamasomas/metabolismo , Inflamasomas/antagonistas & inhibidores , Simulación del Acoplamiento Molecular , Antirreumáticos/farmacología , Antirreumáticos/química , Antirreumáticos/síntesis química , Antirreumáticos/uso terapéuticoRESUMEN
Since synovial hypoxic microenvironment significantly promotes the pathological progress of rheumatoid arthritis (RA), hypoxia-inducible factor 1 (HIF-1) has been emerged as a promising target for the development of novel therapeutic agents for RA treatment. In this study, we designed and synthesized a series of diaryl substituted isoquinolin-1(2H)-one derivatives as HIF-1 signaling inhibitors using scaffold-hopping strategy. By modifying the substituents on N-atom and 6-position of isoquinolin-1-one, we discovered compound 17q with the most potent activities against HIF-1 (IC50 = 0.55 µM) in a hypoxia-reactive element (HRE) luciferase reporter assay. Further pharmacological studies revealed that 17q concentration-dependently blocked hypoxia-induced HIF-1α protein accumulation, reduced inflammation response, inhibited cellular invasiveness and promoted VHL-dependent HIF-1α degradation in human RA synovial cell line. Moreover, 17q improved the pathological injury of ankle joints, decreased angiogenesis and attenuated inflammation response in the adjuvant-induced arthritis (AIA) rat model, indicating the promising therapeutic potential of compound 17q as an effective HIF-1 inhibitor for RA therapy.
Asunto(s)
Artritis Reumatoide , Isoquinolinas , Transducción de Señal , Animales , Humanos , Masculino , Ratas , Antirreumáticos/farmacología , Antirreumáticos/química , Antirreumáticos/síntesis química , Artritis Experimental/tratamiento farmacológico , Artritis Experimental/patología , Artritis Experimental/metabolismo , Artritis Reumatoide/tratamiento farmacológico , Artritis Reumatoide/metabolismo , Artritis Reumatoide/patología , Relación Dosis-Respuesta a Droga , Descubrimiento de Drogas , Subunidad alfa del Factor 1 Inducible por Hipoxia/antagonistas & inhibidores , Subunidad alfa del Factor 1 Inducible por Hipoxia/metabolismo , Isoquinolinas/química , Isoquinolinas/farmacología , Isoquinolinas/síntesis química , Estructura Molecular , Transducción de Señal/efectos de los fármacos , Relación Estructura-Actividad , Quinolonas/síntesis química , Quinolonas/química , Quinolonas/farmacologíaRESUMEN
Exponemos el caso de un varón de 73 años con antecedentes de una artritis reumatoide por la que había recibido tratamiento con sales de oro (aurotiomalato sódico) por vía intramuscular durante 8 años. Tras suspender dicho tratamiento desarrolló una pigmentación con tonalidad verdosa en dorso de manos y antebrazos. Las escleras presentaban una pigmentación similar, pero el resto de las mucosas, el pelo y las uñas estaban respetadas. El estudio histopatológico demostró la presencia de gránulos en el interior de macrófagos, así como libres en la dermis. El tratamiento continuado durante largos períodos con sales de oro puede producir una pigmentación en áreas fotoexpuestas denominada crisiasis. Aunque las mucosas están libres, las escleras pueden verse afectadas. Histopatológicamente se caracteriza por la acumulación de gránulos de oro en el citoplasma de los macrófagos dérmicos. Debido a la tendencia actual de utilizar terapias más agresivas para la artritis reumatoide, prácticamente la única patología en que se sigue usando sales de oro, probablemente la crisiasis sea cada vez más rara. (AU)